NewCardio (NWCI) is a development-stage diagnostic company, focuses on the research, development, and commercialization of products and services for the non-invasive diagnosis and monitoring of cardiovascular disease. It also involves in the cardiac safety assessment of various drugs that are under development.

The company’s technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by 12-lead electrocardiogram electrodes.

NewCardio has three products under various stages of development: QTinno, an automated software tool suite, which provides QT interval data from a range of electrocardiograms; VisualECG, a set of algorithms and tools that provide a method to assess cardiac electrical activity in time and space; and CardioBip, a mobile electrocardiogram transtelephonic system comprising a mobile electrocardiogram recording and transmitting device, and a diagnostic center, which receives, processes, and analyzes the data.

Information provided by Capital IQ.

http://www.newcardio.com

Track One - 4:30 pm